WO2007087637A3 - Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity - Google Patents

Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity Download PDF

Info

Publication number
WO2007087637A3
WO2007087637A3 PCT/US2007/061167 US2007061167W WO2007087637A3 WO 2007087637 A3 WO2007087637 A3 WO 2007087637A3 US 2007061167 W US2007061167 W US 2007061167W WO 2007087637 A3 WO2007087637 A3 WO 2007087637A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
cognitive impairment
inhibitors
methods
activity
Prior art date
Application number
PCT/US2007/061167
Other languages
French (fr)
Other versions
WO2007087637A2 (en
Inventor
Joseph Harding
John Wright
Peter Meighan
Stala Meighan
Original Assignee
Univ Washington
Joseph Harding
John Wright
Peter Meighan
Stala Meighan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Joseph Harding, John Wright, Peter Meighan, Stala Meighan filed Critical Univ Washington
Publication of WO2007087637A2 publication Critical patent/WO2007087637A2/en
Publication of WO2007087637A3 publication Critical patent/WO2007087637A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Particular aspects provide methods for treating cognitive impairment, comprising administration of a therapeutically effective amount of at least one matrix metalloproteinase (MMP) inhibitor sufficient to provide for at least one of precluding, alleviating, reversing, or inhibiting cognitive impairment characterized by sustained elevated expression and/or activity of at least one MMP. Persistent elevations in the expression of MMPs in the hippocampus of aged individuals have a detrimental effect on hippocampal synaptic plasticity, and are an underlying cause of cognitive deficits associated with ageing, and particular aspects therefore provide novel compositions and methods comprising use of MMP (e.g., MMP3 and/or MMP9, etc.) inhibitors to treat age-related cognitive impairment (e.g., cognitive decline). Additional embodiments comprise inhibition of MMP-3 and at least one other MMP (e.g., MMP-9, etc). Exemplary MMP inhibitors comprise a zinc-binding hydroxamate moiety (or a non-hydroxamate zinc-binding moiety), and a peptide or peptidomimetic backbone capable of binding at least one MMP.
PCT/US2007/061167 2006-01-26 2007-01-26 Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity WO2007087637A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76238806P 2006-01-26 2006-01-26
US60/762,388 2006-01-26

Publications (2)

Publication Number Publication Date
WO2007087637A2 WO2007087637A2 (en) 2007-08-02
WO2007087637A3 true WO2007087637A3 (en) 2007-11-29

Family

ID=38309963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/061167 WO2007087637A2 (en) 2006-01-26 2007-01-26 Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity

Country Status (1)

Country Link
WO (1) WO2007087637A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090263495A1 (en) 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
WO2009113320A1 (en) * 2008-03-13 2009-09-17 株式会社ヤクルト本社 Mmp inhibitor
JP5539965B2 (en) 2008-04-28 2014-07-02 レバレジオ コーポレイション Compositions and methods for treating multiple sclerosis
CN106518845B (en) 2011-08-30 2019-09-13 Chdi基金会股份有限公司 Kynurenin -3- monooxygenase inhibitor, pharmaceutical composition and its application method
SG11201700341PA (en) 2014-07-17 2017-02-27 Chdi Foundation Inc Methods and compositions for treating hiv-related disorders
CN106333954A (en) * 2016-08-19 2017-01-18 重庆医科大学 Application of CL82198 in preparation of medicine for preventing and/or treating Alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US6417229B1 (en) * 1999-10-01 2002-07-09 Pfizer Inc α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
US6417229B1 (en) * 1999-10-01 2002-07-09 Pfizer Inc α-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRANZKE ET AL.: "Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs", THE EMBO JOURNAL, vol. 21, no. 19, 2002, pages 5026 - 5035 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428464B2 (en) 2011-08-30 2016-08-30 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
WO2007087637A2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
WO2007087637A3 (en) Compositions and methods using matrix metalloproteinase (mmp) inhibitors for treating cognitive impairment characterized by persistent or sustained mmp expression and/or activity
EP1880719A3 (en) Composition for prophylaxis or treatment of urinary system infection and method thereof
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
BRPI0407195A (en) histone deacetylase inhibitor, composition, and method for inhibiting histone deacetylase in a cell
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
WO2006105304A8 (en) Phenyl and pyridyl lta4h modulators
BR0304648A (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
EP2573069A3 (en) Inhibitors of histone deacetylase and prodrugs thereof
EP1841463A4 (en) Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2006091395A3 (en) Inhibitors of akt activity
MX2010005343A (en) 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity.
WO2001070675A3 (en) Inhibitors of histone deacetylase
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2006087206A3 (en) Androgen receptor-dependent gene expression control by inhibiting the amine oxidase activity of lysine-specific demethylase (lsd1)
EA200900571A1 (en) COMPOSITIONS CHK1 INHIBITORS
DK1718322T3 (en) Synergistic compositions with FK-228
WO2007117557A3 (en) Diaminopropanol renin inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
WO2007117560A3 (en) Piperidine and morpholine renin inhibitors
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
WO2008087643A3 (en) Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
DE60327075D1 (en) THE INFLAMMATORY REACTIONS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07710345

Country of ref document: EP

Kind code of ref document: A2